The UvA-LINKER will give you a range of other options to find the full text of a publication (including a direct link to the full-text if it is located on another database on the internet).
De UvA-LINKER biedt mogelijkheden om een publicatie elders te vinden (inclusief een directe link naar de publicatie online als deze beschikbaar is in een database op het internet).
 Embargo until October 26 2013
 Embargo tot 26 oktober 2013
 Embargo until October 26 2013
 Embargo tot 26 oktober 2013
 Embargo until October 26 2013
 Embargo tot 26 oktober 2013

Search results

Query: faculty: "FNWI" and publication year: "2012"

AuthorM.A. Boks
TitleModulation of immune tolerance: the role of tolerogenic dendritic cells and TNFα
PromotorS.M. van Ham
Co-promotorsJ.A. ten Brinke, J.J. Zwaginga
Date26-10-2012
Year2012
Pages149
ISBN978-94-6182-153-9
FacultyFaculty of Science
Institute/dept.FNWI: Swammerdam Institute for Life Sciences (SILS)
Keywordstolerance induction; anti-TNFα-biologicals; regulatory T cells; IL-10; tolerogenic dendritic cells
AbstractThis thesis describes the role of tolerogenic DC and anti-TNFα agents in tolerance induction. IL-10-generated tDC potently induce Treg, while inhibiting CD4+ T cell proliferation and cytokine production by Th1 and Th2 cell subsets. Anti-TNFα shares this dual function; inducing IL-10 production and a regulatory phenotype and function in naïve CD4+ T cells, and at the same time counteracting CD4+ effector T cell priming by inhibiting activation status, survival and IFNγ production. Anti-TNFα upregulates inhibitory molecules galectin-3, legumain, GARP and LAG-3 which may be involved in (cell contact-dependent) suppressive function, as is described for natural Treg. In addition, chemokine and chemokine receptor expression are altered after TNFα neutralization, suggesting a change in chemoattraction by Treg and chemotaxis of Treg, thereby regulating the encounter with other immune cells. The picture emerges that tDC and anti-TNFα agents synergistically enhance immune suppression. Combination therapy of tDC and anti-TNFα agents may therefore improve tolerance induction therapy in patients with TNFα-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, multiple sclerosis and inflammatory bowel diseases.
LanguageEnglish
Document typeDissertation
Download papers
Document finderUvA-Linker